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PSEUDOMONAS AERUGINOSA INFECTIONS AF-
TER LUNG TRANSPLANTATION: COMPARISION BE-
TWEEN CYSTIC FIBROSIS AND OTHER END STAGE
LUNG DISEASE RECIPIENTS
Berthoud G, Nicod L, van Delden C*; Division of
Infectious Diseases, University Hospital Geneva,
Geneva, CH-1211 Switzerland 14
OBJECTIVE: To compare the incidence and out-
come of Pseudomonas aeruginosa colonization and
infections after lung transplantation between cys-
tic ﬁbrosis (CF) and other end stage lung disease
recipients.
METHODS: Retrospective review of all lung trans-
plantations performed at the University Hospital
Geneva from June 1993 to June 2000.
RESULTS: 51 lung transplantations were performed
during the study period. 12 patients were trans-
planted for end stage CF and 39 for other end stage
lung diseases. 3 CF and 16 non-CF recipients had
died by June 2000. Before transplantation, all the
11 CF recipients were colonized by P. aeruginosa
as compared to 7 non-CF recipients (p < 0.005).
Following transplantation, 11 CF recipients had
respiratory tract colonization by P. aeruginosa
compared to 17 non-CF recipients (p = 0.007).
3 out of the 11 colonized CF recipients had a P.
aeruginosa infection (as accessed by a compati-
ble clinical picture, and >104 CFU on a BAL) as
compared to 14 out of the 17 colonized non-CF
recipients (p = 0.08). Whereas none of the CF re-
cipients died from a P. aeruginosa infection, 5
non-CF recipients died of a P. aeruginosa infection
(P = 0.11).
CONCLUSIONS: In our study there was a trend for
more frequent P. aeruginosa colonization after lung
transplantation in CF than in non-CF recipients. Al-
though not statistically signiﬁcant, as compared to
CF recipients, P. aeruginosa colonization of non-CF
recipients seems to bemore frequently complicated
by severe infections.
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A CASE REPORT OF DISSEMINATED CUTANEOUS
LEISHMANIASIS IN A KIDNEY TRANSPLANTED PA-
TIENT
Haghpanah B*, Hejazi SH; Mycology & Parasitology
Dept. Medical School Isfahan University of Medical
Sciences
A 62 year old male patient received a kidney trans-
plant from his 24 years old son. He was hospitalized
due complications of the graft twice.
A lesion of cutaneous leishmaniasis was located on
his leg. This parasite was demonstrated by direct
microscopy. The ﬁrst lesion spread to other sites
of the body which at present time total 56 such
lesions and may be due to the use of immunosup-
pressive drugs. These lesions also were positive in
direct microscopy. The Leishmanin skin test was
negative and his spleen and liver have normal size,
no involvement of lymph nodes was seen.
Prevention and health education about leishma-
niasis is very important in transplanted patients in
endemic areas. Due to impairment of the immune
system, dissemination may occur in such patients.
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POSTTRANSPLANTATION IMMUNOLOGIC MONI-
TORING OF RENAL ALLOGRAFT RECIPIENTS TO
DIFFERENTIATE INFECTIONS AND GRAFT REJEC-
TION
Metodiev Kr1, Lazarova P2, Kisselova A3; 1Dept.
Immunology, Medical University, Varna-Bulgari,
2Clinical Lab., District Hospital ‘‘St. Anna’’,
arna-Bulgaria, 3Lab. Allergology & Immunology,
Dental Faculty, Soﬁa-Bulgaria
The two major complications after any solid organ
transplantation are the graft rejection (a result of
immune conﬂict) and infection processes (bacte-
rial, viral, fungal). Each one requires a very speciﬁc
and absolutely adequate therapeutic approach: im-
munosuppression or anti-infective agents. This is
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the reason we need a very exact differentiation be-
tween both.
Our model of immunologic monitoring (IM) in-
cludes several highly informative tests to evaluate
the dynamic immunoreactivity of the recipients of
renal allografts (108 patients, 64 male, 44 female).
The T-helper and T-supressor cell activity and the
index Th/Ts, the macrophage activity NBT-test, the
enzymes SDH, alpha-GPDH, LDH and their quanti-
tative levels, the NK- and K-cell activity, the RBT,
the monocyte test for Fc and C3 receptors, the
warm and cold antibodies, the TNAB morphologic
analysis, as well as the level of immunodefﬁciency,
allow us to determine the immune state of the
patients in different phases after transplantation
and more important, to predict the forth-coming
complications. Thus, the proper and exact differ-
entiation diagnosis of graft rejection and infections
requires the adequate therapy for each case and
eliminates the possible mistakes, such as high-dose
immunosuppression when no rejection is detected
or anti-infective agents when only the immune
conﬂict is demonstrated.
Our model of IM allows a precise evaluation of
the immunoreactivity of the recipient of renal al-
lografts in any phase after transplantation and can
predict the post-transplantation complications.
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THE CLINICAL IMPACT OF GANCICLOVIR PROPHY-
LAXIS ON THE OCCURRENCE OF BACTEREMIA IN
ORTHOTOPIC LIVER TRANSPLANTATION (OLT)
Munoz L, Ruthazer R, Poutsiaka D, Hadley S, Free-
man R, Rohrer R, Angelis M, Cooper J, Barefoot L,
Snydman DR*; Tufts New England Medical Center,
Boston, Ma
OBJECTIVE: Cytomegalovirus (CMV) infection or ex-
posure to a CMV seropositive liver has been shown
to be an independent predictor of bacteremia in
OLT. However, prevention of CMV infection through
use of anti-CMV prophylaxis has not previously been
examined with respect to the rates of bacteremia
after orthotopic liver transplantation.
METHODS: We analyzed the impact of CMV prophy-
laxis with ganciclovir on rates of bacteremia by
examining 192 consecutive liver transplant recipi-
ents from 1994—1999 with two year follow-up. Data
were analyzed using time dependent survival anal-
ysis with Cox proportional hazards models and Ka-
plan Meier plots.
RESULTS: There were 29 episodes of bacteremia in
192 (15%) OLT patients. Multivariate analysis of risk
factors for bacteremia showed that ganciclovir pro-
phylaxis for 14 or more days (hazard ratio 0.40, 95%
CI 0.18 to 0.87, p = 0.02), and biliary anastomo-
sis using a choledochojejunostomy (HR 0.47, 95% CI
0.19 to 0.85, p = 0.02), were independently associ-
ated with a decreased risk of bacteremia, while in-
vasive fungal infection (HR 3.64, 95% CI 1.4 to 9.4,
p < 0.001) was associated with an increased risk.
CONCLUSION: Among factors associated with bac-
teremia in liver transplantation, use of prophylactic
ganciclovir is independently associated with a sig-
niﬁcant reduction in bacteremia post OLT and sup-
ports the hypothesis that suppression of CMV with
antiviral prophylaxis has beneﬁts in addition to the
direct effects on CMV.
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TYPE-1 CD8+ TCELL IMMUNERESPONSES AGAINST
EBV ANTIGENS ARE PRESERVED IN STABLE IM-
MUNOSUPPRESSED SOLID ORGAN TRANSPLANT
RECIPIENTS
Popescu I, Macedo C, Zeevi A, Shapiro R, Abu-Elmagd
K, Storkus W, Fung JJ, Metes D*; Thomas E. Starzl
TE Transplantation Institute, University of Pitts-
burgh, Pittsburgh, PA
OBJECTIVES: It is well accepted that a type-1
(IFN-gamma) predominance of T cell immunity is
critical for efﬁcient control of EBV replication and
latency establishment. In this study we analyzed
the immune polarization of anti-EBV CD8+ T cell
responses (IFN-gamma/IL-5 ratio) in immunosup-
pressed (IS) stable solid organ transplant (SOTx)
patients. Our goal is to understand the impact of
IS on the increased susceptibility and progression
towards post transplant lymphoproliferative disor-
ders (PTLD) observed with SOTx patients, and to
determine if ex vivo type-1 anti-EBV CTL generation
for prevention or treatment of PTLD is feasible.
METHODS: 8 EBV+/HLA-A02+ IS stable SOTx pa-
tients and 8 EBV+/HLA-A02+ healthy controls
were recruited for this study. CTLs were gener-
ated by co-culturing for 10 days autologous T cells
with DC loaded with a mixture of three HLA-A02
restricted peptides derived from latent (EBNA3A,
LMP2) and lytic (BMLF1) EBV Ags. ELISPOT assays
for IFN-gamma and IL-5 production were performed
on freshly isolated lymphocytes or on ex vivo gen-
erated EBV-speciﬁc CTLs.
RESULTS: When resting patients’ lymphocytes were
stimulated with PMA/Ionomycin, they exhibited
a type-1 polarization of immune responses (ratio
= 6.4) that was comparable to healthy individuals
(ratio = 4.5). Although the frequency of CD8+ T
cells from IS SOTx patients releasing IFN-gamma
in response to EBV-peptide stimulation had a ten-
dency to be lower than in healthy controls, resting
lymphocytes from patients still showed comparable
IFN-gamma/IL-5 ratios for (EBNA3A = 3.9, LMP2
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= 5.1, and BMLF1 = 4.2) to healthy individuals
(EBNA3A = 6.7,LMP2 = 4.8, and BMLF1 = 5.5). Af-
ter 10 days of ex vivo co-cultures, anti-EBV speciﬁc
CTLs were successfully generated from patients
and normal controls. The EBV-speciﬁc effectors
displayed a mixed IFN-gamma/IL-5 cytokine re-
activation upon ex vivo stimulation. However a
signiﬁcant predominance of type-1 polarization of
EBV-speciﬁc CD8+ T cell responses was detected
in patients (EBNA3A = 4.2, LMP2 = 4.6, and BMLF1
= 4.6) as well as in healthy controls (EBNA3A= 4.9,
LMP2 = 4.4, and BMLF1 = 4.2).
CONCLUSION: Our results suggest that IS stable
SOTx patients display an overall predominance of
type-1 immune responses (including against EBV
Ags), comparable to healthy controls. These data
imply that ex vivo DC-based protocols can be suc-
cessful in eliciting EBV-speciﬁc CD8+ T cells from
IS stable SOTx patients for immunotherapy and
vaccination.
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RESULTS OF LAMIVUDINE THERAPY RENAL ALLO-
GRAFT RECIPIENTS WITH CHRONIC HEPATITIS B
Zubkin M*, Chervinko V, Zolotorevski V, Selkova E,
Evseev A, Kozhokar Y, Frolov A, Stahanova V, Stenina
I, Baranova F, Taranov V, Balakirev E, Novozhenov V;
State Institute of Postgraduated Medical Education,
Nephrology Center, Moscow, Russia
INTRODUCTION: Efﬁcacy of lamivudine therapy was
studied in 16 renal allograft recipients (AR) with
chronic hepatitis B (CHB): 10 males, 6 females, age
from 23 to 64 (45± 3.1) years.
METHODS: Therapy was started in 54.3± 10.0
months after kidney transplantation. Transplant
function was normal in 13 patients. 3 patients had
transplant dysfunction with mild increase in crea-
tinine concentration. All AR received prednisolone
and cyclosporin A immunosuppression, one was
treated with mofetil mycofenolate (CellCept) as
well. All patients had DNA HBV positive. 10 of them
were HBeAg(+), and 6 — HBeAg(−). Lamivudine
dose varied depending on GFR. Treatment duration
was 9 to 23 (13.8± 0.8) months.
RESULTS: Improvement of CHB severity was
achieved in 8 AR: 2 patients showed viral remission
(negative HBV DNA test), 1 demonstrated biochem-
ical remission (normalised ALT activity), and 5
patients had both biochemical and viral remission.
Lamivudine therapy was effective in 5 of 6 patients
with HBeAg(−) and only in 3 of 10 HBeAg(+) CHB
patients (p = 0.04). Liver biopsy was performed
in 14 patients. No correlation was found between
response to the lamivudine therapy and periportal
necrosis extent, portal inﬂammation or intralobu-
lar dystrophy. The response however was depended
on ﬁbrosis severity (p = 0.03). In 2 patients the ef-
fect of lamivudine therapy appeared in 4—5 months
after beginning. In 6 other patients 8—12 months
of therapy was needed for the effect to occur.
All AR with positive response to lamivudine ther-
apy showed viremia relapse in 1—3 months after
lamivudine withdrawal. An increase in ALT activity
after lamivudine withdrawal was detected only in 2
patients. Second liver biopsy showed a decrease in
the histological activity index (HAI, Knoddel et al.,
1981) from 16 to 6 and from 9 to 5, respectively, in
2 of 3 patients with a remission. No change in HAI
was found in a patient without a remission.
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EX VIVO FLOWCYTOMETRIC DETERMINATION OF
INTRACYTOPLASMIC EXPRESSION OF TNF-, IL-1
and IL-6 IN A KIDNEY TRANSPLANT PATIENT
Andreeva H*, Petrova P, Daniel V1, Sadeghi M1;
Center of Clinical Immunology, University School of
Medicine, Pleven Bulgaria; 1Department of Trans-
plantation Immunology, University of Heidelberg,
Germany
OBJECTIVE: Many functional features of periph-
eral blood lymphocytes and antigen presenting
cells (monocytes and dendritic cells) are impor-
tant for the graft viability and for the development
of acute kidney transplant rejection. Activated in
vivo monocytes are the most important source of
pro-inﬂammatory cytokines (TNF-, IL-1, IL-6) and
additionally contribute to T-cells priming. Our aim
was to determinate by ﬂow cytometry the intra-
cytoplasmic expression of TNF-, IL-1, IL-6 ex vivo
and in vitro in monocytes after transplantation
during the early post transplant period in renal
transplanted patients(RTP).
MATERIALS & METHODS: We examined monocytes
taken from 20 RTP, separated in three groups ac-
cording to the status of the graft: Stable Renal Graft
(SRG) n = 10; Acute Graft Rejection (AGR) n = 5;
Acute Tubular Necrosis (ATN) n = 5 and 10 healthy
adults (HA). A two-color ﬂow cytometric technique
was used to measure (in the presence of Monensin)
the intracellular spontaneous and lip polysaccha-
ride (LPS)-stimulated TNF-, IL-1, and IL-6 produc-
tion in monocytes (CD14+) of whole blood cultures.
RESULTS: The spontaneous TNF- production was
signiﬁcantly lower in monocytes from SRG and AGR
groups compared to HA. The percentage for IL-1
positive unstimulated monocytes did not differ sig-
niﬁcantly among all studied groups. The percentage
of IL-6 positive unstimulated monocytes could not
reach 1% for patient’s groups compared to HA (2.8;
0.56). The LPS-stimulated intracellular production
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of TNF- after 4h. of culture showed no differ-
ence in the percentage positive cell but signiﬁcantly
higher was the Mean Fluorescence Intensity (MFI) in
ATN and AGR compared to SRG and HA. The stim-
ulated IL-1 production was signiﬁcantly increased
as percentage positive monocytes by SRG and AGR
signiﬁcantly increased was the MFI for AGR as well.
Signiﬁcantly increased were the percentages IL-6
positive stimulated monocytes from HA and AGR.
This result was conformed with the signiﬁcantly el-
evated levels of MFI for AGR, which was higher than
the MFI for SRG and ATN. Secondly, the MFI of IL-6
positive monocytes from ATN were signiﬁcantly in-
creased compared to those from SRG group.
CONCLUSION: Cytokine ﬂow cytometry enables one
to study, ex vivo, i.e., without any stimulation of
the cells, and in vitro after appropriate stimulation,
the bioactivity of monocytes from renal transplants
patients. The dynamical changes inmonocytic prim-
ing according to days after transplantation will be
discussed. The results clearly show an activation of
the monocytes cytokine network in patients with
AGR. Increased TNF-, IL-1, and IL-6 reﬂect an ac-
tivation of the T-cells immune response, which may
compromise the graft viability.
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DIFFERENT SPECIMEN TYPES FOR MONITORING
EPSTEIN-BAR VIRUS LOAD IN SOLID ORGAN TRANS-
PLANT RECIPIENTS
Preiksaitis JK1, Lee B2, Pang XL2; 1Depart of Med, U
of Alberta, 2Provincial laboratory for Public Health,
Edmonton, Alberta, Canada
OBJECTIVE: EBV viral load is becoming an impor-
tant diagnostic tool for the prevention and man-
agement of post-transplant lymphoproliferative
disease (PTLD). This study is to determine the op-
timal specimen type for the measurement of EBV
viral load in solid organ transplant (SOT) recipients.
METHODS: Quantitative EBV viral load was prospec-
tively assayed in peripheral blood mononuclear
cells (PBMC), whole blood (WB) and plasma frac-
tions of 554 samples from 48 SOT patients. DNA was
extracted with the QIAgen DNA mini kits. PCR re-
action was performed by LightCycler using primers
and probes from the EBNA1 gene. Namalwa cell
line was the quantitative standard.
RESULTS: The threshold of detection for EBV DNA
was 375 copies/ml for plasma, 60 copies/ug DNA for
WB and PBMC. EBV was detected in 12.1% in plasma
(67/554), 44.4% in PBMC (246/554) and 44.5% in
WB (247/554). The number of specimens with dis-
cordant results between WB & PBMC was 17/554
(3%) (p = 1). Greater discordance was observed be-
tween PBMC & plasma, 179/554 (32%) and plasma
& WB, 176/554 (31%) (p < 0.001). EBV viral load in
WB and PBMC for specimens that tested negative,
positive and indeterminate in plasma fractions was
signiﬁcantly different (p < 0.001).
Mean
copies/
g DNA
Negative
Plasma
Indeterminate
Plasma
(<375 copies/ml)
Positive Plasma
(Mean = 4756 ±
11503 copies/ml)
PBMC 2457 ± 8181 4403 ± 5151 25315 ± 36008
WB 1681 ± 4972 3881 ± 6263 23569 ± 35401
There is excellent correlation of log EBV viral
load between WB and PBMC (R2 = 0.94, slope
= 0.98, P < 0.01), and poorer correlation between
plasma and PBMC and plasma and WB (R2 = 0.28,
& R2 = 0.31, p < 0.01, respectively).
CONCLUSIONS: WB and PBMC fractions are valu-
able for the surveillance of EBV primary infection
or early detection of EBV reactivation in SOT re-
cipients, while plasma is an adequate specimen
type for the diagnosis of EBV in patients with high
viral loads, e.g. existing PTLD. Overall, WB is the
preferred specimen type for monitoring EBV viral
load in SOT because of the simple requirement for
specimen processing, reduced cost, comparable
sensitivity and excellent correlation with PBMC.
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LEUKOREDUCTION IN PANCREATIC ISLETS RE-
DUCES THE RISK OF CYTOMEGALOVIRUS (CMV)
TRANSMISSION
Preiksaitis JK*, Shapiro J, Lakey J, Korbutt G, Bigam
D, Kneteman N, LeBlanc B, Fenton J; Provincial Lab-
oratory for Public Health (Microbiology), Depart-
ments of Medicine and Surgery, University of Alberta
Hospital, Edmonton, Alberta, Canada
OBJECTIVE: CMV is readily transmitted from CMV
seropositive (+) solid organ donors (D) to CMV
seronegative (−) recipients (R) with contaminating
latently infected leukocytes the likely source of
infection. The risk of CMV transmission by cellular
blood products is known to be signiﬁcantly reduced
and perhaps eliminated when these products are
leukoreduced (<5× 106 leukocytes/unit). We ex-
amined the risk of CMV transmission by pancreatic
islet transplantation, where leukocyte contami-
nation is likely to be lower than in solid organ
transplantation (SOT).
METHODS: We compared CMV mismatched (R−D+)
islet transplant (Tx) recipients to a control group
of CMV mismatched SOT recipients transplanted
between Mar. 99 and Sept. 01 for evidence of
CMV transmission. Patients were monitored weekly
for antigenemia/viremia (2—12 weeks post Tx).
Quantitative antigenemia was determined by
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immunoﬂuorescence (IFA) using a monoclonal an-
tibody to CMV pp65 antigen (Clonab CMV, Biotest
AG, Dreieich). Viremia was detected by IFA with
MRC-5 shell vials (Meriﬂuor CMV, Meridian Diagnos-
tics Inc, Cincinnati, Ohio, USA). CMV IgG serology
(Dade Behring Enzygnost, Marburg, Germany) was
assayed in all patients at a minimum of six months
post Tx. Patients were identiﬁed as infected if they
seroconverted to CMV IgG and/or demonstrated (+)
antigenemia/viremia. Leukocytes in islet prepara-
tions were quantitated by IFA using CD45 antibody
(DakoCytomation Carpinteria, CA, USA).
RESULTS: None of the 17 mismatched islet re-
cipients had evidence of CMV infection. In con-
trast 50/62 (80.6%) SOT recipients demonstrated
evidence of CMV infection (p < 0.0001). Six
seropositive multiorgan donors providing organs to
seronegative SOT and islet recipients transmitted
CMV infection to all six SOT recipients but none of
the islet recipients. The mean number of leuko-
cytes transfused into D+R- islet recipients was
estimated to be 18.8± 2.19× 106.
CONCLUSION: Islet preparations have low numbers
of contaminating leukocytes, a factor contributing
to the low risk of transmitting CMV infection in this
setting.
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AN EFFECTIVE TOOL FOR QUANTITATIVE DETEC-
TION OF CMV-DNA FOR MONITORING OF IMMUNO-
COMPROMISED PATIENTS
Ziegelmaier S, Rudolf M, Wach S*, Grewing T; artus
GmbH, Hamburg
OBJECTIVE: Cytomegalovirus (CMV) infections in
immunocompromised patients can cause serious to
fatal diseases. Especially in organ transplant recip-
ients after solid-organ transplantation, CMV seems
to be the major health threat: on the one hand by
possible reactivation of the dormant virus by im-
munosuppressive agents and on the other hand by
receiving a primary CMV infection after solid-organ
transplantation. For protection of the recipient it
is essential to test the organ donor for CMV. If pos-
sible, the use of CMV infected organs for transplan-
tation should be avoided. Considerable progress
has been made in the use of antiviral therapy to
treat CMV infection following organ transplanta-
tions. In monitoring this CMV treatment, sensitive
and quantitative assays for measurement of viral
load are highly important. In addition, early track-
ing of viral load can avoid unneccessary treatment
with anti-viral agents and can reduce costs.
METHODS: We developed a sensitive, speciﬁc, reli-
able and quantitative CMV detection system, which
is based on real-time PCR technology. For nucleic
acid ampliﬁcation we chose a CMV speciﬁc re-
gion which excludes unspeciﬁc detection of other
pathogens. Different quantiﬁcation standards of
deﬁned dilutions allow exact quantiﬁcation of the
pathogen load. Besides this speciﬁc ampliﬁcation
system, we designed a heterologous system which
acts as an internal control.
RESULTS: With the RealArtT CMV PCR Kit we devel-
oped a ready-to-use assay for real-time PCR which
allows a distinct differentiation of CMV positive and
negative samples and a reliable quantiﬁcation of
the pathogen load within a broad range. The analyt-
ical sensitivity has been determined as highly sensi-
tive by probit analysis. Simultaneous ampliﬁcation
of the internal control and the speciﬁc sample in
one reaction tube excludes false negative results.
CONCLUSION: While CMV infection is still a pro-
found problem in organ transplantation, promising
anti-viral therapies are in progress. Monitoring of
these therapies requires highly sensitive and quan-
tifying CMV detection systems. The RealArtT CMV
PCR Kit fulﬁlls all requirements for such a reliable,
quick and signiﬁcant CMV detection, which allows
proper quantiﬁcation of the pathogen load. On the
basis of PCR technology the RealArtT CMV PCR Kit
represents an essential tool for the successful man-
agement of CMV disease.
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UNCOMMON FUNGAL INFECTIONS AFTER LUNG
TRANSPLANTATION
Compte N, Rodriguez-Villalobos H, Knoop C, del
Marmol V, De Dobbeleer G, Estenne M, Nolard N,
Jacobs F*; Erasme University Hospital, Scientiﬁc
Institute of Public Health, Brussels, Belgium
OBJECTIVES: Unusual mould infections due to
non-Candida and non-Aspergillus mycosis are
increasingly reported after solid organ transplan-
tation (TX). Their diagnosis and management con-
stitute new challenges for health professionals.
METHODS: We retrospectively reviewed all cases
of uncommon fungal infections which occurred be-
tween 1995 and 2004 in adult lung transplant recip-
ients followed at our institution.
RESULTS: 10 patients (pts) developed fungal infec-
tions due to unusual moulds. Half of them occurred
in 2003. Two infections developed during the ﬁrst 2
months but the others after a median 32 months (19
to 68) after TX. These infections consisted in skin
and soft tissue (5 pts), pulmonary (3), gastric (1)
and disseminated (1) infections. All pts were highly
immunosuppressed because of acute or chronic re-
jection episodes. Seven had viral infections (4 CMV,
2 VZV and 1 EBV) during the 3months period preced-
ing fungal infection. The skin and soft tissue lesions
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consisted in phaeohyphomycosis presenting as sub-
cutaneous abscesses due to Alternaria alternata
(2), large ulcerated lesions of the lower limb due
to primary cryptococcosis (1 pt) and subcutaneous
bottom abscess due to Trichophyton interdigitale
(1 pt). Three pts developed pulmonary nodules. In
2 of them, biopsy of the lesions showed C. neo-
formans and Mucor spp. respectively. In the third
pt, Acrophialophora fusispora, Rhizopus spp. and
A. fumigatus were the only pathogens found on
sputum culture. The 2 early infections consisted
in gastric perforation due to Rhizopus microsporus
invasion of the gastric wall and in disseminated
Pseudoallescheria boydii infection in a previously
colonized cystic ﬁbrosis patient. Six patients died,
and in 3, death was directly due to fungal infec-
tion. All patients with skin infections improved with
surgery combined with voriconazole treatment.
CONCLUSIONS: We observed an increasing inci-
dence of unusual fungal infections after lung TX.
Skin and soft tissue infections had a good prognosis
but other infections can be life-threatening. Due to
the difﬁculties for the diagnosis, as many of them
presented as skin and soft tissue infections, biop-
sies and appropriate cultures of all new skin lesions
are warranted. These infections also require close
collaboration among clinicians, microbiologists and
pathologists.
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LATE POST RENAL TRANSPLANT TUBERCULOSIS
Tan TT*, Tan BH, Heng D, OngWY; Singapore General
Hospital
OBJECTIVES: More Tuberculosis (TB) infections oc-
curred during the ﬁrst few post-transplant trans-
plant years. A series of late post renal transplant TB
prompted a review in our institution. The ﬁndings
are reported here.
METHODS: We retrospectively analysed the case
records of our renal transplant patients who had
been treated or diagnosed with TB (tuberculosis)
from 1992 to 2002. During this period, there were
646 renal transplant patients.
RESULTS: There were 29 cases of TB; in 27 of them,
culture was positive for M. tuberculosis. Two pa-
tients were treated for TB on clinical and radiolog-
ical grounds. The median duration from transplant
to diagnosis of TB was 78 months. The infection was
extra-pulmonary in 41% and was disseminated in
38% of the patients. Extra-pulmonary sites involved
included the gastrointestinal tract (6 patients), the
osteoarticular system (5 patients), the urogenital
tract (3 patients), blood/bone marrow (3 patients),
a soft tissue abscess, pericardial ﬂuid and cere-
brospinal ﬂuid (1 patient each). Disseminated dis-
ease occurred more commonly among patients who
had been transplanted in India and developed post-
transplant TB. The most common presentation was
fever. Classical symptoms (e.g., night sweats) were
reported only in 1 patient. Positive cultures came
mainly (70%) from invasive procedures. The highest
incidence of post-transplant TB extends beyond the
ﬁrst post-transplant year. Fifty-nine percent of our
transplant recipients were diagnosed with TB after
the ﬁfth post-transplant year. This is different from
a variety of reports that have surfaced over the
years. This later presentation could be the result
of a higher regional endemicity of TB as the doses
of immunosuppressants in our transplant recipients
with TBwere not inordinately high. In the 12months
prior to the diagnosis of TB, no patient had been on
an increasing dose of a calcineurin inhibitor, only
7.7% had had a pulse of methylprednisolone and
only 11.5% had received an anti-lymphocyte agent.
A 3-drug regimen was used in 27 patients (92%). Du-
ration of treatment varied from 9 to 24 months. The
mean duration of follow-up was 39.8 months (1 to
120 months). Three patients had recurrences.
CONCLUSION: Diagnosis of TB in renal transplant pa-
tients often means invasive diagnostic procedures.
Recognition that TB may be a late event is impor-
tant so that this cohort of patients can get timely
investigations and treatment.
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Rhodococcus equi CAVITARY PNEUMONIA ASSOCI-
ATED WITH POST-TRANSPLANT LYMPHOPROLIF-
ERATIVE DISEASE (PTLD) IN A PEDIATRIC HEART
TRANSPLANT RECIPIENT
Renoult E1, Buteau C1, Turgeon N2, Tapiero B1;
1Infectious Diseases Division, 2Department of Pe-
diatrics and Department of Microbiology and Im-
munology, Hoˆpital Sainte-Justine, University of
Montreal, Canada
A 14-year-old girl with end stage congenital heart
disease underwent heart transplantation (recip-
ient CMV seropositive, EBV seronegative; donor
CMV seronegative and EBV serology unknown).
She had an early episode of steroid-treated rejec-
tion. Immunosuppression consisted of cyclosporine,
azathioprine and prednisone. Seven months af-
ter transplantation, she was hospitalized with
fever (39 ◦C), asthenia, cough, nasal congestion,
abdominal pain, and ulcerated lesions in the
mouth. A CT scan revealed a pulmonary nodule
(11× 15mm) and multiple hypodense lesions in
the liver without lymphadenopathy. Biopsy of one
of the hepatic masses showed extensive necro-
sis and features suggestive of PTLD. EBV PCR was
positive in the blood and in a biopsy specimen of
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the oral ulcers. Concomitantly, CMV reactivation
was detected. A diagnosis of PTLD presenting as
a multifocal (hepatic and pulmonary) nodular in-
volvement was considered. Initial management
included reduction of immunosuppressive treat-
ment with antiviral therapy. Over the next 25
days, a pancreatic nodule and a para-sternal mass
appeared and intravenous cyclophosphamide and
prednisone were added. At day 39 post-admission,
the patient developed temperature of 40 ◦C with
hemodynamic unstability, exacerbated cough and
progressive respiratory distress requiring intuba-
tion and mechanical ventilation. A new CT scan
showed an increase of the size (70× 30× 30mm)
of the pulmonary mass with a cavitary abcess con-
taining an air-ﬂuid level. Pancreatic and hepatic
lesions were regressing. A Gram-stained smear
of the purulent material aspirated from the pul-
monary nodule showed many polymorphonuclear
neutrophils, and Gram-positive bacilli. Cultures
of the pulmonary aspirate as well as blood and
sputum showed growth of Rhodococcus equi.. A
core-biopsy of the parasternal mass revealed highly
atypical cells compatible with involvement by
PTLD; culture of the specimen was negative. The
anti-infectious treatment consisted on intravenous
vancomycin, meropenem, erythromycin and oral ri-
fampicin. The patient’s condition improved slowly.
Erythromycin and meropenem were stopped af-
ter six weeks. Vancomycin and rifampicin were
continued for 5 and a half months. Two years af-
ter the end of therapy, the patient is doing well
and is PTLD free. This young transplant recipient
presented with multinodular (hepatic and pul-
monary) lesions initially considered of the same
nature, namely tumoral. Actually, the patient suf-
fered from both a likely hepatic and para-sternal
PTLD and a subsequently identiﬁed infectious
pulmonary process, reﬂecting her profoundly im-
munocompromised state, probably enhanced by
the immune modulation induced by herpes group
viruses.
025
INFECTIOUS COMPLICATIONS IN RENAL TRANS-
PLANT RECIPIENTS; CHANGING EPIDEMIOLOGY IN
RECENT YEARS
Thyagarajan R, Chandrasekar PH*, Haririan A,
Morawski K, Gruber SA, Garnick J, El-Amm J, West
MS, Granger DK, Sillix D, Alangaden GJ; Wayne
State University School of Medicine, Detroit MI, USA
OBJECTIVE: We investigated the impact of cur-
rent antimicrobial prophylactic regimens on the
epidemiology of infectious complications in renal
transplant patients (pts).
METHODS: A retrospective review of the microbi-
ologically- documented infections occurring in 131
pts who underwent renal transplantation at our
center between 7/1/01 and 2/11/04 was con-
ducted. Pts received Thymoglobulin (50%) or basil-
iximab (50%) for induction, and were maintained
on mycophenolate mofetil, prednisone, and either
tacrolimus (73%) or sirolimus (27%). Antimicro-
bial prophylaxis included perioperative cefazolin,
trimethoprim/sulfamethaxazole (TMP/SMX) for 6
mo & valganciclovir for 3 mo.
RESULTS: There were 74 infections in 49 pts. 23
pts with ≥1 rejection episode experienced 1.12 in-
fections/pt, compared with 0.44 infections/pt in
those without rejection (P < 0.001). The most com-
mon infections were: UTI 31/74 (42%), bacteremia
9/74 (12%), wound infection 9/74 (12%), pneumo-
nia 6/74 (8%) and CMV antigenemia 6/74 (8%). Of
23 infections in the ﬁrst mo, UTI (48%) and wound
infection (22%) were the most common. 27 infec-
tions occurred after 3 months: UTI 37%, bacteremia
30% and CMV antigenemia 15%. In 32 pts with UTI,
the most common pathogens were Escherichia coli
(25%) and Enterococcus spp. (19%). In 14 pts with
early UTI (<1 mo), enterococci were the predom-
inant pathogen (44%), with no cases of E. coli. Af-
ter 1 mo, E. coli was the predominant uropathogen
(67%). Of 6 pts with CMV antigenemia, 3 had D+/R−
serostatus, 5 cases were diagnosed after 3 mo, and
none had tissue invasive disease. All pts responded
to ganciclovir therapy. There were no cases of PCP
or BK virus nephropathy. Invasive fungal infection
occurred in 2 pts, one with disseminated Rhizo-
pus infection and the other with Candida albicans
peritonitis and fungemia. Both pts died, account-
ing for the 1.5% infectious mortality rate in this
cohort.
CONCLUSIONS: Current antimicrobial prophylaxis
has resulted in a signiﬁcant decrease in the in-
cidence of opportunistic infections after kidney
transplantation. Prophylaxis with valganciclovir is
effective in reducing CMV antigenemia and elim-
inating tissue-invasive disease. Enterococci has
replaced E. coli as the predominant uropathogen
in the early posttransplant period. Invasive fungal
infections are still associated with high mortality.
026
A CASE OF BK VIRUS-ASSOCIATED HEMORRHAGIC
CYSTITIS IN A LUNG TRANSPLANT RECIPIENT AND
REVIEW OF THE LITERATURE
Grim SA*, Jaffe HA, Clark NM; University of Illinois
at Chicago
BACKGROUND: The polyomavirus BK (BKV) is an
increasingly recognized cause of disease among
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organ transplant recipients, particularly those re-
ceiving renal allografts. BKV predominantly affects
the kidneys and urinary tract, tissues thought to
be the primary sites of viral latency. BKV causes
polyomavirus nephropathy (PVN), which most of-
ten presents as a tubulointerstitial nephritis (TIN).
Hemorrhagic and nonhemorrhagic cystitis may also
develop as a result of BKV infection, although BKV
cystitis is typically seen in bone marrow transplant
(BMT) recipients.
PATIENT CASE: A 51 year-old female with sclero-
derma developed gross hematuria in the presence
of stable renal function three weeks post bilat-
eral lung transplantation. CT scan of the abdomen
showed a markedly enlarged and inﬂamed urinary
bladder. Urine cytology revealed the presence of
decoy cells and polymerase chain reaction (PCR)
for BKV nucleic acids was repeatedly positive in
blood and urine. Urine viral culture, including for
adenovirus, was negative. Due to persistent severe
hemorrhage from the bladder, cystectomy was re-
quired. No antiviral therapy was administered for
BKV. One month post cystectomy, PCR for BKV nu-
cleic acids in blood and urine remained positive
but the patient experienced no change in renal
function.
METHODS: To identify the frequency with which
BKV-associated urinary tract disease occurs in
non-renal solid-organ (NRSOT) recipients, a MED-
LINE search was performed (1966 to March 2004)
using the following search terms: BK virus, poly-
omavirus, nephropathy, hemorrhagic cystitis (HC)
and transplant. Secondary references were re-
viewed.
RESULTS: Disease of the urinary tract due to BKV
has rarely been reported in NRSOT recipients.
There is only one report of PVN occurring in the
native kidneys of a NRSOT recipient. Regarding
BKV-related bladder disease, late-onset HC not re-
lated to chemotherapeutic agents occurs in 5—40%
of BMT patients with associated BK viruria at a rate
of 10—100%. There are also two published reports
of BKV-associated HC in HIV-seropositive patients
and BKV-related HC has also been noted in renal
transplant recipients. However, our case appears
to be the ﬁrst report of HC due to BKV in a NRSOT
recipient.
DISCUSSION: Renal disease due to BKV is uncom-
mon in NRSOT recipients although has occasionally
been reported. Hemorrhagic and nonhemorrhagic
cystitis may also be caused by BKV, and is typically
seen in the setting of bone marrow transplantation.
There are limited data concerning BKV-related dis-
ease in the native kidneys or bladders of NRSOT re-
cipients. This report suggests that clinicians should
consider BKV in the differential diagnosis of HC in
all immunocompromised persons, not just BMT re-
cipients.
027
BK VIRUS CLINICAL EXPERIENCE IN RENAL TRANS-
PLANTATION
Patel N*, Stafford-Coit C, Garces J, Garcia-Diaz J;
Ochsner Clinic Foundation, Department of Infec-
tious Diseases, New Orleans, Louisiana 70121
The human polyoma viruses BK and JC were ﬁrst
isolated in 1971. In renal transplant recipients,
BK virus (BKV) causes tubulointerstial nephritis
(BK nephropathy) and induces ureteral stenosis.
While rejection rates have decreased recently
with the advent of new immunosuppressants,
the prevalence of BK virus nephropathy has in-
creased. Since the ﬁrst case of BKV was reported
at Ochsner Clinic Foundation (OCF) in Septem-
ber 2000, we aimed to determine the incidence
of BKV in renal transplant patients at OCF and
evaluate whether current experimental treatment
of BKV is effective. We retrospectively analyzed
200 cases of renal transplant between Septem-
ber 2000—December 2003 to determine the in-
cidence of BKV. Of the 200 cases, 120 patients
experienced elevation in creatinine and underwent
renal biopsy. In 12 of these patients, biopsy re-
sults were positive for polyoma virus. In our kid-
ney transplant population six per one hundred
patients receiving renal transplant were at risk
for developing active BKV. With the increase in
new cases, others have examined the treatment
of BKV virus. At OCF only one case of BKV has
been treated with cidofovir. A 54-year-old male
was diagnosed with BK nephropathy in July 2002.
A rise in creatinine was noted 12 months post
transplantation and the patient underwent renal
biopsy. Biopsy results showed focal tubular injury,
with the tubular nuclei showing viral inclusions,
and an immunostain was positive for polyoma
virus. Mycophenolate and tacrolimus were discon-
tinued and cyclosporine was started. At the time
of initial infusion of cidofovir (0.25mg/kg), the
patient’s viral load was 845,000 copies/ml and
creatinine was 2.6mg/dl. After the fourth infu-
sion (approximately 8 weeks later), the patient’s
viral load had decreased to 2,000 copies per ml,
but creatinine did not improve (3.2mg/dl). In
our patient the viral load was reduced with the
treatment of cidofovir. Similar results have been
published in literature. Cidofovir is a promis-
ing new drug and more patients with BKV in-
fection/nephropathy need to be evaluated in a
blinded, comparative trial to be able to elucidate
its true effect.
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DONOR TRANSMITTED B19 INFECTION IN RENAL
TRANSPLANT PATIENT
Patel N*, Quintero C, Garcia-Diaz J; Ochsner Clinic
Foundation, Department of Infectious Diseases,
New Orleans, Louisiana 70121
Parvovirus B19 has a wide variety of manifestations
depending on the immunologic and/or hematologic
status of the patient. Persistent infection in the im-
munocompromised host can cause chronic anemia
and pure red blood cell aplasia (PRCA). We present
a case of Parvovirus B19 infection acquired from
a cadaveric kidney that led to PRCA in the recipi-
ent. The patient is a 34 y/o female who received
a cadaveric renal transplant for renal failure due
to focal segmental glomerulosclerosis. Ten weeks
following the transplant she presented with weak-
ness secondary to anemia. After an extensive work
up a bone marrow biopsy revealed no red blood
cell precursors and few proerythroblasts consistent
with PRCA. Parvovirus B19 serologies returned neg-
ative but a Parvovirus B19 DNA by PCR viral load
returned with a level of >1,000,000 copies/ml. The
patient’s pre-transplant serologies were also nega-
tive. Donor lymph node tissue, however, was pos-
itive for Parvovirus B19 by PCR assay. Our patient
responded to decrease in immunosuppression and
2mg/kg immunoglobulin. We could only ﬁnd two
other cases of donor transmitted B19 infection re-
sulting in PRCA in renal transplants. Given the high
incidence of Parvovirus B19 in the adult popula-
tion, and as solid organ transplant is increasing, the
prevalence of this infection is likely to increase.
Parvovirus B19 should be considered in kidney trans-
plant patients who present with severe refractory
anemia.
029
FUNGI ISOLATED FROM THE CLINICAL SPECIMENS
OF THE PATIENTS UNDERGOING LIVER SURGERY;
EPIDEMIOLOGY AND SUSCEPTIBILITY OF THE FUN-
GAL STRAINS
Kawecki D1*, Swoboda-Kopec E1, Wroblewska M1,
Stelmach E1, Rynkiewicz S1, Krawczyk M2, Luczak
M1; 1Department of Medical Microbioloby, Medical
University of Warsaw,Warsaw, Poland, 2Department
of General and Liver Surgery, Medical University of
Warsaw, Warsaw, Poland
AIMS: Estimation of frequency of fungal isolates
from specimens obtained from immunocompro-
mised patients hospitalised in 2003, in the Depart-
ment if General and Liver Surgery of the Medical
University of Warsaw, and assessment of their sus-
ceptibility to antifungal agents.
METHODS: Specimens sent for culture comprised
the swabs from the throat, peritoneum, stool,
swabs from the drains, blood, nasal cavity and
other. The isolation and identiﬁcation of cultured
fungi was done according to standard mycological
procedures and commercially available test ID 32C
and API Candida Tests (bioMerieux). Susceptibility
of the strains to antifungal agents was made by
Fungitest assay (Biorad).
RESULTS: Fungal cultures were positive in 174
clinical samples in 2003. In total 187 strains of
yeast-like fungi andmoulds were isolated. Themost
commonly isolated species were: C. albicans 114-
strains (61%), C. glabrata 38- strains (20,3%), C.
parapsilosis 11- strains (5,9%), C. krusei 7- strains
(3,7%), C. inconspicua 6- strains (3,2%), C. tropicalis
3 (1,6%), Aspergillus ﬂavus 3 (1,6%). All strains were
susceptible to amphotericin B, non-albicans Can-
dida strains were characterised by lower suscepti-
bility to many commonly used antifungal agents.
CONCLUSIONS: The most common fungal pathogen
isolated from clinical specimens was C. albicans
(61%). Emergence of multi-drug resistant Candida
spp. warrants modiﬁcation of antifungal therapy
and proﬁlaxis, particularly in immunocompromised
patients.
030
INCIDENCE AND OUTCOME OF 82 EPISODES OF
BACTEREMIA FOLLOWING 300 CONSECUTIVE
SOLID ORGAN TRANSPLANTS
Góngora-Rubio F, Nakaya F, Shiratsuchi GY, Arroyo
PC, Domingos TA, Bestetti RB, Abbud F M, Camelo
FC, Góngora DVN; CCIH—CINTRANS, Hospital de
Base, FUNFARME, DEPARTAMENTO DE INFECTOLO-
GIA, FAMERP, São José do Rio Preto, São Paulo, Brazil
OBJECTIVE: To determine relative rates, outcome,
frequency of etiologic agent origin of bloodstream
infection in 300 consecutive Solid Organ Transplan-
tation (SOT) recipients (heart 23, liver 117 and kid-
ney 160).
METHODS: Concurrently collected data were re-
viewed retrospectively between June 1997 and
November 2003. We studied all adults (>18 years)
who underwent SOT and survived at least 48 hours.
RESULTS: Fifty nine patients (19.7%) developed 82
episodes of bacteremia (0.27 episodes/patient).
Heart recipients experienced a higher rate 6/23
(26%) than either liver 23/117 (19.7%) or kidney
30/160 (18.7%). Eighty four bacteria were isolated
in 82 bacteremic episodes. Staphylococcus aureus
was the predominant bacteria isolated 21/84 (25%)
and predominated at all three sites. Gram-negative
bacilli (54/84) represented 64.3%. Sixty four
episodes (78%) were hospital acquired and 18/82
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(22%) were community acquired. Mortality asso-
ciated with the bacteremic episodes was 32.2%.
There was no difference in mortality in those with
adequate or inadequate empirical treatment com-
pared with speciﬁc etiologic treatment (p = 0.4).
CONCLUSIONS: These results conﬁrm the impor-
tance of Staphylococcus aureus as the predominant
bacteria in all three transplants and thus inter-
ventions are needed to develop more effective
strategies for prevention.
031
PREVALENCE OF ANTI-CYTOMEGALOVIRUS ANTI-
BODIES IN THE SERUM OF ACUTE RADIATION SYN-
DROME CONVALESCENTS
Chumak AA*, Abramenko IV, Boichenko PK, Pleskach
OY, Petrakov VM, Marchenko JM; Research Centre
for Radiation Medicine, Academy of Medical Sci-
ences of Ukaraine, Kyiv
Persisting cytomegalovirus infection inﬂuences on
the time course of somatic and oncologic diseases
being a severe complication in the cases of organ
and tissue transplantation, in HIV-infected and
other immunocompromised hosts.
OBJECTIVE: The aim of thework was to estimate the
prevalence of antibodies against cytomegalovirus
(CMV) in convalescents who had endured an acute
radiation syndrome (ARS) in 1986 during Chernobyl
NPP accident emergency works.
METHODS: We studied 118 males convalescents of
ARS (1st group). Second group consisted from age
matched 118 males living in Kyiv city; they had not
taken part in Chernobyl NPP accident emergency
works: 36 blood donors and 82 patients with dif-
ferent somatic diseases. Anti-CMV antibodies were
investigated by ELISA kits.
RESULTS: Anti-CMV antibodies were found in 70.3%
people of 2nd control group. Presence of anti-
CMV positively correlated with such somatic
diseases as chronic gastritis, arthrites, diabetes
mellitus, hematological diseases, lymphadenopa-
thy, frequent acute respiratory diseases. Anti-CMV
antibodies prevalence among ARS convalescents
reached 93.8%. It correlated with existence of
chronic gastritis, chronic obstructive and non-
obstructive bronchitis, hematological disturban-
cies, lymphadenopathy and absorbed radiation
dose.
CONCLUSION: A high prevalence of anti-CMV an-
tibodies was found in the serum of ARS convales-
cents. CMV reactivation was connected to certain
diseases and directly correlated with absorbed
doses of irradiation.
